EXEL Exelixis, Inc. - Common Stock
$54,22
Kurs · Aug 20, 2026
Fundamentaldaten per Aug 5, 2026
52W-Spanne
$34–$58
86% of range
Analystenbewertung
HOLD
26 analysts
Kursziel
$53
P/E (TTM)
18.8
ROE
37.3%
Nettogewinnmarge
33.7%
Über Exelixis, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Mehr lesen
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
History
Exelixis was founded in 1994; the scientific founders were Spyridon Artavanis–Tsakonas, at Yale at that time, and Corey Goodman and Gerry Rubin who were then at the University of California, Berkeley. George Scangos joined the company as CEO in 1996. The business plan was to use model organisms (fruit flies, nematodes, and zebrafish) and functional genomics to identify pathways and biological targets that could be exploited in the fields of agriculture and medicine. It eventually set up a subsidiary, Exelixis Plant Sciences, for the agricultural work.
By 2000, Exelixis had left the radical exploratory phase behind and became focused on drug discovery and had a chemical library of 4 million compounds. The company went public that year, after withdrawing its offering the week before; it raised $118 million in a down market.
In 2002, the company signed a broad alliance with GSK to discover new drugs in the fields of cancer, inflammatory diseases, and vascular conditions; GSK paid it $30 million in cash, bought $14 million in stock at twice the market rate, and committed to providing Exelixis with $90 million in research funding; it also offered loan financing of up to $85 million.
By 2002, the company had limited its internal efforts to cancer, and had settled its strategy on discovering and developing drugs that could inhibit targeted small sets of tyrosine kinases that are needed for cancer formation, growth, and metastasis. The sets of TKs had been identified by means of its prior functional genomics work. This approach was controversial at the time; most companies try to selectively target just one protein in their discovery efforts.
In 2006, Exelixis partnered with Daiichi Sankyo on compounds that targeted mineralocorticoid receptors; esaxerenone was part of this collaboration. In 2007, the company partnered its MEK inhibitor program with Genentech; cobimetinib (at that time XL-518) was part of this collaboration. Exelixis had filed an IND on XL-518 prior to the partnership, committed to funding and running the Phase I trial, and retained rights to co-market it in the US.
In 2008, the company partnered its lead cancer drug candidate, XL-184 (which would become called cabozantinib) and another cancer candidate, XL-281, with Bristol Myers Squibb; BMS returned the rights to XL-184 to Exelixis in 2010 and returned the rights to other drug candidate in 2011.
In 2010, Scangos departed as CEO to take over at Biogen and the company appointed Michael M. Morrissey as president and CEO; Morrissey had joined the company in 2000 as Vice President of Discovery Research. At that time the company had eight drugs in clinical trials.
Exelixis' first drug approval came in 2012, when cabozantinib was approved for medullary thyroid cancer, an orphan indication. It was approved in Europe in 2014.
Exelixis invested heavily in exploring cabozantinib in other cancers, betting the future of the company on the drug. In 2014 the drug failed a Phase III trial in prostate cancer, and the company laid off 70% of its employees.
In 2015, Genentech and Exelixis won FDA approval for cobimetinib for certain forms of melanoma.
In March 2016, Exelixis licensed to Ipsen worldwide rights (outside the US, Canada, and Japan) to market cabozantinib.
In April 2016, the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer and the same was approved in Europe in October of that year.
In December 2017, the FDA granted approval for the use of cabozantinib for first line treatment of kidney cancer and in 2018 approval for first-line treatment was approved in Europe.
Finance
Pricing
Cabometyx (cabozantinib)
In 2023, the Institute for Clinical and Economic Review (ICER) identified Cabometyx (cabozantinib) as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Cabometyx's wholesale acquisition cost rose by 7.5%, leading to an additional $86 million in costs to U.S. payers.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
EXEL Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$54.22
Marktkapitalisierung
$13.75B
P/E (TTM)
18.8
EPS (TTM)
$2.78
Umsatz (TTM)
$2.32B
Dividendenrendite
—
ROE
37.3%
Verschuldungsgrad
—
52W-Spanne
$34 – $58
EXEL Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$2.32B
2016-12-31
→
2026-01-02
EPS
$2.78
2017-12-29
→
2026-01-02
Freier Cashflow
$876M
2017-12-29
→
2026-01-02
Margen
33.7%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
EXEL
Peer-Median
P/E (TTM)
18.8
28.5
P/S (TTM) (K/V (TTM))
5.9
20.1
P/B (K/B)
6.4
12.9
Price / FCF (Kurs / FCF)
15.7
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
EXEL
Peer-Median
Operating Margin (Betriebsgewinnmarge)
37.6%
—
Net Profit Margin (Nettogewinnmarge)
33.7%
-48.4%
ROA
27.0%
-28.4%
ROE
37.3%
-49.2%
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
EXEL
Peer-Median
Current Ratio (Liquiditätsgrad)
3.6
5.0
Quick Ratio
3.3
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
EXEL
Peer-Median
Revenue YoY (Umsatz YoY)
7.0%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
12.9%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
18.6%
—
EPS YoY (EPS VjV)
58.0%
—
Net Income YoY (Nettogewinn YoY)
50.1%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
EXEL
Peer-Median
EXEL Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
26 Analysten
- Starker Kauf 5 19,2%
- Kauf 8 30,8%
- Halten 12 46,2%
- Verkauf 1 3,8%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
17 Analysten · 2026-08-20
Median
$52.00
Jetzt
$54.22
Tief
$41.00
Hoch
$66.00
Median-Ziel
$52.00
-4,1%
Mittelwert-Ziel
$53.00
-2,2%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.08%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $0.82 | $0.80 | 0.02% |
| 31. März 2026 | $0.79 | $0.72 | 0.07% |
| 31. Dezember 2025 | $0.88 | $0.82 | 0.06% |
| 30. September 2025 | $0.69 | $0.63 | 0.06% |
| 30. Juni 2025 | $0.65 | $0.57 | 0.08% |
| 31. März 2025 | $0.55 | $0.37 | 0.18% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | $191M | $37M | |
| Cost of Revenue | $84M | $76M | $73M | $58M | $53M | $36M | $33M | $26M | $15M | $7M | $4M | |
| R&D Expense | $825M | $910M | $1.04B | $892M | $694M | $548M | $337M | $182M | $112M | $96M | $96M | |
| SG&A Expense | $519M | $492M | $543M | $460M | $402M | $293M | $228M | $206M | $159M | $116M | $57M | |
| Operating Expenses | $1.45B | $1.56B | $1.66B | $1.41B | $1.15B | $877M | $598M | $415M | $287M | $220M | $159M | |
| Operating Income | $872M | $605M | $171M | $201M | $287M | $110M | $369M | $439M | $166M | $-28M | $-121M | |
| Interest Expense | · | · | · | · | · | · | $0 | $0 | $9M | $33M | $41M | |
| Other Non-op | $-198.0K | $-133.0K | $93.0K | $-197.0K | $-184.0K | $912.0K | $680.0K | $397.0K | $-4M | $5M | $-381.0K | |
| Pretax Income | · | · | · | · | · | $131M | $398M | $452M | $159M | $-70M | $-162M | |
| Income Tax | $159M | $160M | $50M | $52M | $63M | $19M | $77M | $-238M | $4M | $0 | $55.0K | |
| Net Income | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | $-70M | $-162M | |
| EPS (Basic) | $2.88 | $1.80 | $0.65 | $0.57 | $0.73 | $0.36 | $1.06 | $2.32 | $0.52 | · | $-0.77 | |
| EPS (Diluted) | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | · | $-0.77 | |
| Shares (Basic) | 271,567,000 | 290,030,000 | 318,151,000 | 321,526,000 | 314,884,000 | 308,271,000 | 302,584,000 | 297,892,000 | 293,588,000 | · | 209,227,000 | |
| Shares (Diluted) | 281,863,000 | 296,132,000 | 321,464,000 | 324,556,000 | 322,359,000 | 318,001,000 | 315,009,000 | 312,803,000 | 312,003,000 | · | 209,227,000 | |
| EBITDA | $901M | $633M | $197M | $222M | $300M | $119M | $378M | $444M | $167M | · | · |
Bilanz 27
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $482M | $217M | $263M | $501M | $647M | $319M | $267M | $315M | $183M | $152M | $142M | |
| Short-term Investments | $577M | $894M | $732M | $807M | $820M | $887M | $586M | $379M | $205M | $268M | · | |
| Receivables | $287M | $265M | $237M | $215M | $283M | $161M | $119M | $163M | $77M | $40M | · | |
| Inventory | $22M | $22M | $17M | $33M | $27M | $21M | $13M | $10M | $7M | $3M | · | |
| Prepaid Expense | $76M | $68M | $68M | $62M | $58M | $57M | $27M | $31M | $9M | $5M | · | |
| Current Assets | $1.44B | $1.47B | $1.32B | $1.62B | $1.83B | $1.45B | $1.01B | $897M | $485M | $469M | · | |
| PP&E (Net) | $99M | $119M | $129M | $111M | $104M | $67M | $49M | $51M | $26M | $2M | · | |
| PP&E (Gross) | $231M | $220M | $209M | $171M | $145M | $102M | $74M | $68M | $49M | $27M | · | |
| Accum. Depreciation | $132M | $101M | $80M | $61M | $41M | $35M | $26M | $17M | $23M | $25M | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | |
| Other Non-current Assets | · | · | · | · | $131M | $73M | $53M | $8M | $12M | $1M | · | |
| Total Assets | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Accounts Payable | $30M | $38M | $34M | $33M | $24M | $24M | $12M | $11M | $10M | $7M | · | |
| Short-term Debt | · | · | · | · | · | · | · | · | $0 | $80M | · | |
| Current Liabilities | $406M | $404M | $394M | $324M | $338M | $205M | $143M | $105M | $115M | $269M | · | |
| Capital Leases | $173M | $191M | $190M | $190M | $51M | $49M | $48M | $12M | $15M | · | · | |
| Other Non-current Liabilities | $104M | $109M | $94M | $69M | $8M | $721.0K | $2M | $1M | $2M | $541.0K | · | |
| Total Liabilities | $683M | $703M | $678M | $583M | $406M | $258M | $200M | $135M | $370M | $506M | · | |
| Long-term Debt | · | · | · | · | · | · | · | · | $0 | $189M | · | |
| Total Debt | · | · | · | · | · | · | · | · | $0 | · | · | |
| Common Stock | $262.0K | $282.0K | $303.0K | $324.0K | $319.0K | $312.0K | $305.0K | $300.0K | $296.0K | $290.0K | · | |
| Paid-in Capital | $2.23B | $2.34B | $2.44B | $2.54B | $2.43B | $2.32B | $2.24B | $2.17B | $2.11B | $2.07B | · | |
| Retained Earnings | $-77M | $-99M | $-173M | $-34M | $-217M | $-448M | $-559M | $-880M | $-1.83B | $-1.98B | · | |
| AOCI | $3M | $-1M | $-4M | $-15M | $-758.0K | $4M | $3M | $-701.0K | $-347.0K | $-416.0K | · | |
| Stockholders' Equity | $2.16B | $2.24B | $2.26B | $2.49B | $2.21B | $1.88B | $1.69B | $1.29B | $285M | $89M | $-141M | |
| Liabilities + Equity | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Shares Outstanding | 262,483,000 | 281,732,000 | 302,793,000 | 323,951,000 | 318,842,000 | 311,627,000 | 304,831,000 | 299,876,000 | 296,209,000 | 289,923,798 | 227,960,943 |
Cashflow 17
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $29M | $29M | $26M | $21M | $14M | $9M | $8M | $5M | $1M | $1M | $1M | |
| Stock-based Comp | $113M | $94M | $106M | $108M | $120M | $105M | $57M | $41M | $24M | $23M | $22M | |
| Deferred Tax | $126M | $-59M | $-133M | $-60M | $47M | $15M | $71M | $-244M | $0 | $0 | $0 | |
| Restructuring | $21M | $34M | $0 | $0 | · | · | · | $0 | $-32.0K | $63M | $1M | |
| Other Non-cash | $-167M | $116M | $127M | $112M | $-10M | $-32M | $70M | $-76M | $-14M | · | · | |
| Operating Cash Flow | $884M | $700M | $333M | $363M | $401M | $209M | $527M | $416M | $166M | $206M | $-141M | |
| CapEx | $8M | $28M | $40M | $28M | $54M | $30M | $13M | $33M | $21M | $2M | $447.0K | |
| Investing Cash Flow | $350M | $-117M | $-27M | $-524M | $-43M | $-131M | $-587M | $-298M | $37M | $-216M | $50M | |
| Net Debt Issued | · | · | · | · | · | · | $0 | $0 | $-186M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $0 | $0 | $146M | |
| Stock Repurchased | $948M | $652M | $550M | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | $-948M | $-652M | $-550M | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $-970M | $-629M | $-546M | $586.0K | $-15M | $-25M | $13M | $10M | $-170M | $20M | $152M | |
| Net Change in Cash | $265M | $-46M | $-240M | $-161M | $343M | $53M | $-48M | $128M | $32M | $10M | $61M | |
| Taxes Paid | $155M | $170M | $186M | $128M | $13M | $4M | $8M | $11M | $538.0K | · | · | |
| Free Cash Flow | $876M | $672M | $293M | $335M | $337M | $179M | $514M | $382M | $144M | · | · | |
| Levered FCF | · | · | · | · | · | · | $514M | $382M | $136M | · | · |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | · | · | |
| Net Margin | 33.7% | 24.0% | 11.3% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | · | · | |
| Pretax Margin | · | · | · | · | · | 13.2% | 41.1% | 52.9% | 35.0% | · | · | |
| EBITDA Margin | 38.8% | 29.2% | 10.7% | 13.8% | 20.9% | 12.1% | 39.0% | 52.0% | 36.9% | · | · | |
| ROA | 27.0% | 17.7% | 6.9% | 6.4% | 9.7% | 5.6% | 19.4% | 66.4% | 24.7% | · | · | |
| ROE | 37.3% | 23.1% | 9.0% | 7.3% | 10.7% | 6.0% | 19.5% | 62.6% | 82.4% | · | · | |
| ROIC | · | · | · | · | · | 5.0% | 17.7% | 52.0% | 56.6% | · | · |
Liquidität & Solvenz 4
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 | 7.1 | 7.1 | 8.5 | 4.2 | · | · | |
| Quick Ratio | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 | 6.7 | 6.8 | 8.1 | 4.1 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 0.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 19.1 | · | · |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.8 | 0.7 | · | · | |
| Inventory Turnover | 3.8 | 3.8 | 2.9 | 1.9 | 2.2 | 2.1 | 2.9 | 3.2 | 3.0 | · | · | |
| Receivables Turnover | 8.4 | 8.6 | 8.1 | 6.5 | 6.5 | 7.1 | 6.9 | 9.8 | 7.4 | · | · |
Wachstumsraten 9
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.0% | 18.5% | 13.6% | 12.3% | 45.3% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.9% | 14.8% | 22.8% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 18.6% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 58.0% | 170.8% | 16.1% | -22.2% | 105.7% | · | · | · | · | · | · | |
| EPS CAGR 3Y | 70.6% | 34.7% | 22.9% | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 51.3% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 50.1% | 150.9% | 14.0% | -21.1% | 106.7% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 62.5% | 31.1% | 22.9% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 47.6% | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 14
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | · | $37M | |
| Net Income TTM | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | · | $-162M | |
| Market Cap | $11.44B | $9.57B | $7.26B | $5.20B | $5.83B | $6.25B | $5.19B | $5.83B | $9.00B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $8.62B | · | · | |
| P/E | 15.7 | 19.3 | 36.9 | 28.6 | 25.4 | 57.3 | 16.7 | 8.8 | 62.0 | · | -7.3 | |
| P/S | 4.9 | 4.4 | 4.0 | 3.2 | 4.1 | 6.3 | 5.4 | 6.8 | 19.9 | · | · | |
| P/B | 5.3 | 4.3 | 3.2 | 2.1 | 2.6 | 3.3 | 3.1 | 4.5 | 31.6 | · | · | |
| P / Tangible Book | 5.5 | 4.4 | 3.3 | 2.1 | 2.7 | 3.4 | · | · | · | · | · | |
| P / Cash Flow | 12.9 | 13.7 | 21.8 | 14.3 | 14.5 | 29.9 | 9.8 | 14.0 | 54.4 | · | · | |
| P / FCF | 13.1 | 14.3 | 24.8 | 15.5 | 17.3 | 35.0 | 10.1 | 15.2 | 62.3 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | 51.6 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | 59.6 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 19.0 | · | · | |
| Earnings Yield | 6.4% | 5.2% | 2.7% | 3.5% | 3.9% | 1.7% | 6.0% | 11.4% | 1.6% | · | -13.7% |
Gewinn- und Verlustrechnung 14
| Kennzahl | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $629M | $611M | $718M | $598M | $568M | $555M | $818M | $540M | $637M | $425M | $480M | $472M | $470M | $409M | $424M | $412M | |
| Cost of Revenue | $21M | $20M | $27M | $19M | $19M | $19M | $25M | $17M | $18M | $21M | $22M | $19M | $18M | $14M | $16M | $15M | |
| R&D Expense | $212M | $200M | $164M | $199M | $200M | $212M | $111M | $223M | $211M | $228M | $245M | $333M | $233M | $234M | $337M | $199M | |
| SG&A Expense | $148M | $140M | $161M | $124M | $135M | $137M | $81M | $112M | $132M | $114M | $131M | $138M | $142M | $131M | $119M | $115M | |
| Operating Expenses | $380M | $359M | $287M | $361M | $355M | $369M | $303M | $403M | $361M | $396M | $398M | $490M | $392M | $380M | $472M | $329M | |
| Operating Income | $248M | $251M | $431M | $237M | $214M | $187M | $516M | $136M | $276M | $29M | $82M | $-18M | $78M | $29M | $-48M | $83M | |
| Other Non-op | $54.0K | $219.0K | $207.0K | $-49.0K | $50.0K | $-245.0K | $-363.0K | $-29.0K | $-287.0K | $-89.0K | $-137.0K | $289.0K | $-5.0K | $-54.0K | $-337.0K | $-69.0K | |
| Income Tax | $51M | $57M | $43M | $59M | $46M | $46M | $128M | $37M | $67M | $12M | $18M | $5M | $19M | $8M | $-1M | $19M | |
| Net Income | $212M | $210M | $401M | $194M | $185M | $160M | $399M | $118M | $226M | $37M | $86M | $1M | $81M | $40M | $-30M | $73M | |
| EPS (Basic) | $0.85 | $0.81 | $1.57 | $0.72 | $0.68 | $0.57 | $1.43 | $0.41 | $0.78 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| EPS (Diluted) | $0.82 | $0.79 | $1.49 | $0.69 | $0.65 | $0.55 | $1.39 | $0.40 | $0.77 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| Shares (Basic) | 250,808,000 | 258,329,000 | -604,028,000 | 268,421,000 | 272,583,000 | 278,804,000 | -674,091,000 | 285,622,000 | 289,216,000 | 300,757,000 | -645,970,000 | 315,496,000 | 324,205,000 | 324,420,000 | 577,000 | 322,148,000 | |
| Shares (Diluted) | 259,675,000 | 267,322,000 | -609,119,000 | 278,535,000 | 284,393,000 | 288,177,000 | -676,699,000 | 291,478,000 | 293,974,000 | 305,530,000 | -651,367,000 | 319,247,000 | 327,305,000 | 326,279,000 | 136,000 | 325,066,000 | |
| EBITDA | $248M | $258M | · | $237M | $214M | $194M | · | $136M | $276M | $36M | · | $-18M | $78M | $36M | · | $83M |
Bilanz 24
| Kennzahl | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $281M | $226M | $482M | $376M | $164M | $184M | $217M | $258M | $198M | $260M | · | $397M | $464M | $541M | · | $675M | |
| Short-term Investments | $558M | $551M | $577M | $612M | $627M | $848M | $894M | $931M | $804M | $704M | · | $707M | $802M | $773M | · | $872M | |
| Receivables | $322M | $329M | $287M | $310M | $292M | $282M | $265M | $270M | $397M | $241M | · | $248M | $233M | $234M | · | $215M | |
| Inventory | $29M | $27M | $22M | $27M | $23M | $25M | $22M | $21M | $21M | $21M | · | $25M | $29M | $30M | · | $27M | |
| Prepaid Expense | $60M | $76M | $76M | $77M | $74M | $59M | $68M | $70M | $58M | $67M | · | $67M | $62M | $61M | · | $53M | |
| Current Assets | $1.25B | $1.21B | $1.44B | $1.40B | $1.18B | $1.40B | $1.47B | $1.55B | $1.48B | $1.29B | · | $1.44B | $1.59B | $1.64B | · | $1.84B | |
| PP&E (Net) | $93M | $96M | $99M | $105M | $110M | $115M | $119M | $124M | $130M | $127M | · | $121M | $115M | $116M | · | $108M | |
| PP&E (Gross) | · | · | $231M | · | · | · | $220M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $132M | · | · | · | $101M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | $64M | $64M | $64M | · | $64M | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $280M | |
| Total Assets | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Accounts Payable | $39M | $24M | $30M | $25M | $26M | $43M | $38M | $59M | $29M | $26M | · | $26M | $26M | $33M | · | $31M | |
| Current Liabilities | $362M | $371M | $406M | $374M | $336M | $399M | $404M | $394M | $346M | $373M | · | $377M | $340M | $328M | · | $302M | |
| Capital Leases | $166M | $170M | $173M | $176M | $180M | $187M | $191M | $194M | $198M | $201M | · | $191M | $195M | $187M | · | $160M | |
| Other Non-current Liabilities | $123M | $117M | $104M | $113M | $129M | $120M | $109M | $96M | $110M | $101M | · | $62M | $73M | $67M | · | $2M | |
| Total Liabilities | $650M | $658M | $683M | $663M | $645M | $706M | $703M | $685M | $653M | $676M | · | $629M | $615M | $588M | · | $470M | |
| Common Stock | $249.0K | $254.0K | $262.0K | $268.0K | $270.0K | $275.0K | $282.0K | $286.0K | $285.0K | $295.0K | · | $311.0K | $320.0K | $325.0K | · | $323.0K | |
| Paid-in Capital | $2.11B | $2.15B | $2.23B | $2.26B | $2.25B | $2.29B | $2.34B | $2.36B | $2.32B | $2.39B | · | $2.49B | $2.53B | $2.56B | · | $2.51B | |
| Retained Earnings | $-263M | $-216M | $-77M | $-106M | $-220M | $-163M | $-99M | $-90M | $-200M | $-259M | · | $-126M | $11M | $6M | · | $-4M | |
| AOCI | $-2M | $-415.0K | $3M | $4M | $1M | $2M | $-1M | $4M | $-5M | $-5M | · | $-14M | $-14M | $-9M | · | $-18M | |
| Stockholders' Equity | $1.84B | $1.94B | $2.16B | $2.16B | $2.03B | $2.13B | $2.24B | $2.28B | $2.12B | $2.13B | $2.26B | $2.35B | $2.53B | $2.56B | $2.49B | $2.49B | |
| Liabilities + Equity | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Shares Outstanding | 248,885,000 | 253,701,000 | 262,483,000 | 268,098,000 | 270,132,000 | 275,033,000 | 281,732,000 | 285,780,000 | 285,222,000 | 295,032,000 | 302,793,000 | 310,970,000 | 320,253,000 | 324,985,000 | 323,951,000 | 322,541,000 |
Cashflow 12
| Kennzahl | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $8M | $7M | $7M | $7M | $10M | $7M | $7M | $6M | $7M | $6M | $6M | $7M | $6M | $6M | |
| Stock-based Comp | $33M | $29M | $45M | $31M | $36M | $26M | $12M | $23M | $25M | $19M | $24M | $40M | $25M | $17M | $26M | $37M | |
| Restructuring | · | · | $-13M | $20M | $0 | $0 | $34M | $96.0K | $475.0K | $33M | · | $0 | $0 | $0 | · | · | |
| Other Non-cash | · | $5M | · | · | · | $19M | · | · | · | $6M | · | · | · | $21M | · | · | |
| Operating Cash Flow | $308M | $252M | $425M | $290M | $49M | $211M | $377M | $271M | $120M | $69M | $11M | $117M | $121M | $84M | $74M | $110M | |
| CapEx | $7M | $2M | $-16M | $1M | $3M | $3M | $1M | $8M | $7M | $10M | $13M | $9M | $6M | $12M | $10M | $43.0K | |
| Investing Cash Flow | $91M | $-51M | $374M | $25M | $248M | $50M | $-28M | $-217M | $82M | $112M | $62M | $35M | $-74M | $-50M | $-246M | $-69M | |
| Stock Repurchased | $323M | $430M | $486M | $104M | $302M | $284M | $311M | $12M | $264M | $185M | $209M | $217M | $124M | $0 | $0 | $0 | |
| Net Stock Activity | · | $-430M | · | · | · | $-284M | · | · | · | $-185M | · | · | · | · | · | · | |
| Financing Cash Flow | $-344M | $-457M | $-529M | $-104M | $-316M | $-295M | $-289M | $6M | $-262M | $-184M | $-206M | $-220M | $-125M | $5M | $-2M | $-2M | |
| Net Change in Cash | $55M | $-256M | $270M | $212M | $-19M | $-34M | $60M | $60M | $-61M | $-3M | $-134M | $-68M | $-78M | $39M | $-174M | $39M | |
| Free Cash Flow | · | $250M | · | · | · | $208M | · | · | · | $59M | · | · | · | $72M | · | · |
Rentabilität 5
| Kennzahl | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.5% | 41.1% | · | 39.6% | 37.6% | 33.6% | · | 25.2% | 43.3% | 6.9% | · | -3.7% | 16.6% | 7.0% | · | 20.1% | |
| Net Margin | 33.7% | 34.5% | · | 32.4% | 32.5% | 28.7% | · | 21.9% | 35.5% | 8.8% | · | 0.22% | 17.3% | 9.8% | · | 17.8% | |
| EBITDA Margin | 39.5% | 42.3% | · | 39.6% | 37.6% | 35.0% | · | 25.2% | 43.3% | 8.4% | · | -3.7% | 16.6% | 8.7% | · | 20.1% | |
| ROA | 8.2% | 7.8% | · | 6.7% | 6.8% | 5.7% | · | 4.0% | 7.6% | 1.2% | · | 0.04% | 2.7% | 1.4% | · | 2.7% | |
| ROE | 10.9% | 10.3% | · | 8.7% | 8.9% | 7.5% | · | 5.1% | 9.7% | 1.6% | · | 0.04% | 3.3% | 1.7% | · | 3.2% |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.3 | · | 3.8 | 3.5 | 3.5 | · | 3.9 | 4.3 | 3.5 | · | 3.8 | 4.7 | 5.0 | · | 6.1 | |
| Quick Ratio | 3.2 | 3.0 | · | 3.5 | 3.2 | 3.3 | · | 3.7 | 4.0 | 3.2 | · | 3.6 | 4.4 | 4.7 | · | 5.8 |
Effizienz 3
| Kennzahl | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.8 | · | 0.8 | 0.7 | 0.8 | · | 0.7 | 0.6 | 0.5 | · | 0.6 | |
| Receivables Turnover | 2.0 | 2.0 | · | 2.1 | 1.6 | 2.1 | · | 2.1 | 2.0 | 1.8 | · | 2.0 | 2.0 | 1.9 | · | 2.1 |
Bewertung (TTM) 10
| Kennzahl | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.41B | $2.33B | · | $2.26B | $2.30B | $2.16B | · | $2.07B | $2.00B | $1.78B | · | $1.76B | $1.71B | $1.60B | · | $1.52B | |
| Net Income TTM | $801M | $749M | · | $656M | $689M | $541M | · | $382M | $346M | $160M | · | $195M | $265M | $252M | · | $251M | |
| Market Cap | $13.90B | $11.13B | · | $10.75B | $12.47B | $9.51B | · | $7.42B | $6.41B | $7.00B | · | $6.79B | $6.12B | $6.31B | · | $5.06B | |
| P/E | 18.9 | 16.4 | · | 17.5 | 19.5 | 18.8 | · | 20.1 | 19.7 | 48.4 | · | 36.4 | 23.3 | 24.9 | · | 20.1 | |
| P/S | 5.8 | 4.8 | · | 4.8 | 5.4 | 4.4 | · | 3.6 | 3.2 | 3.9 | · | 3.9 | 3.6 | 4.0 | · | 3.3 | |
| P/B | 7.5 | 5.8 | · | 5.0 | 6.1 | 4.5 | · | 3.3 | 3.0 | 3.3 | · | 2.9 | 2.4 | 2.5 | · | 2.0 | |
| P / Tangible Book | 7.8 | 5.9 | · | 5.1 | 6.3 | 4.6 | · | 3.4 | 3.1 | 3.4 | · | 3.0 | 2.5 | 2.5 | · | 2.1 | |
| P / Cash Flow | · | 44.2 | · | · | · | 45.0 | · | · | · | 101.7 | · | · | · | 74.7 | · | · | |
| P / FCF | · | 44.5 | · | · | · | 45.6 | · | · | · | 118.4 | · | · | · | 87.1 | · | · | |
| Earnings Yield | 5.3% | 6.1% | · | 5.7% | 5.1% | 5.3% | · | 5.0% | 5.1% | 2.1% | · | 2.8% | 4.3% | 4.0% | · | 5.0% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| Betriebsgewinnmarge % | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% |
| Nettoergebnis | $783M | $521M | $208M | $182M | $231M |
| Verwässerte EPS | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
Bilanz
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 |
| Quick Ratio | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 |
Cashflow
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $876M | $672M | $293M | $335M | $337M |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Handelssignale Aktuelle Kauf-/Verkaufssignale mit Einstiegspreis und Risiko-Ertrags-Verhältnis
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 812 Einreicher · $9.1B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 129 (+16 vs. Vorquartal) | 61 (-12 vs. Vorquartal) | 242 (+1 vs. Vorquartal) | 280 (+20 vs. Vorquartal) | +14.7M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $732.794.424 | 13.468.010 | 8,01% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $730.617.099 | 13.427.993 | 7,99% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $655.266.268 | 12.043.122 | 7,17% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $595.843.747 | 10.950.997 | 6,52% | Aktien |
| STATE STREET CORP | $542.471.563 | 9.970.071 | 5,93% | Aktien |
| FULLER & THALER ASSET MANAGEMENT, INC. | $485.848.030 | 8.929.389 | 5,31% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $362.702.104 | 6.664.894 | 3,97% | Aktien |
| D. E. Shaw & Co., Inc. | $281.389.313 | 5.171.647 | 3,08% | Aktien |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $237.550.034 | 4.365.926 | 2,60% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $229.058.537 | 4.209.861 | 2,51% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $221.832.835 | 4.077.060 | 2,43% | Aktien |
| ASSETMARK, INC | $186.834.364 | 3.433.824 | 2,04% | Aktien |
| Stephens Investment Management Group LLC | $147.451.698 | 2.710.011 | 1,61% | Aktien |
| NORGES BANK | $146.301.199 | 2.688.866 | 1,60% | Aktien |
| FIRST TRUST ADVISORS LP | $138.383.701 | 2.543.353 | 1,51% | Aktien |
| Caisse de depot et placement du Quebec | $113.950.809 | 2.094.299 | 1,25% | Aktien |
| GOLDMAN SACHS GROUP INC | $106.578.308 | 1.958.800 | 1,17% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $97.484.439 | 1.791.664 | 1,07% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $86.563.209 | 1.590.943 | 0,95% | Aktien |
| Caligan Partners LP | $84.512.985 | 1.553.262 | 0,92% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $66.309.793 | 1.218.706 | 0,73% | Aktien |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $63.086.055 | 1.159.457 | 0,69% | Aktien |
| BANK OF AMERICA CORP /DE/ | $58.788.318 | 1.080.469 | 0,64% | Aktien |
| Robeco Institutional Asset Management B.V. | $56.032.453 | 1.029.819 | 0,61% | Aktien |
| ENVESTNET ASSET MANAGEMENT INC | $51.671.488 | 949.669 | 0,57% | Aktien |
| FMR LLC | $48.839.667 | 897.623 | 0,53% | Aktien |
| Gotham Asset Management, LLC | $48.569.794 | 892.663 | 0,53% | Aktien |
| Swedbank AB | $45.801.141 | 841.778 | 0,50% | Aktien |
| Allspring Global Investments Holdings, LLC | $44.544.520 | 825.510 | 0,49% | Aktien |
| Retirement Systems of Alabama | $44.107.739 | 810.655 | 0,48% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $43.750.809 | 804.095 | 0,48% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $41.924.320 | 770.526 | 0,46% | Aktien |
| Capital Impact Advisors, LLC | $41.061.268 | 754.664 | 0,45% | Aktien |
| BlackRock, Inc. | $40.753.525 | 749.008 | 0,45% | Aktien |
| RHUMBLINE ADVISERS | $35.723.294 | 656.559 | 0,39% | Aktien |
| CANADA PENSION PLAN INVESTMENT BOARD | $35.464.438 | 651.800 | 0,39% | Aktien |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $34.721.830 | 639.680 | 0,38% | Aktien |
| MARSHALL WACE, LLP | $34.322.590 | 630.814 | 0,38% | Aktien |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $34.315.027 | 630.675 | 0,38% | Aktien |
| AMERIPRISE FINANCIAL INC | $32.255.716 | 592.827 | 0,35% | Aktien |
| BARCLAYS PLC | $31.502.574 | 578.985 | 0,34% | Aktien |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $31.496.480 | 578.873 | 0,34% | Aktien |
| Arbejdsmarkedets Tillaegspension | $30.855.911 | 567.100 | 0,34% | Aktien |
| Pictet Asset Management Holding SA | $30.153.926 | 555.438 | 0,33% | Aktien |
| California Public Employees Retirement System | $29.366.600 | 539.728 | 0,32% | Aktien |
| CAPITAL FUND MANAGEMENT S.A. | $28.686.856 | 527.235 | 0,31% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $28.655.734 | 526.663 | 0,31% | Aktien |
| JANUS HENDERSON GROUP PLC | $26.675.806 | 621.814 | 0,29% | Aktien |
| Livforsakringsbolaget Skandia, Omsesidigt | $26.502.106 | 293.703 | 0,29% | Aktien |
| Woodline Partners LP | $26.411.049 | 485.408 | 0,29% | Aktien |
| Driehaus Capital Management LLC | $26.025.500 | 478.322 | 0,28% | Aktien |
| EULAV Asset Management | $25.901.500 | 476.043 | 0,28% | Aktien |
| Squarepoint Ops LLC | $25.774.398 | 473.707 | 0,28% | Aktien |
| Swiss National Bank | $25.648.874 | 471.400 | 0,28% | Aktien |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $25.156.355 | 462.348 | 0,28% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24.600.555 | 452.133 | 0,27% | Aktien |
| IEQ CAPITAL, LLC | $24.580.697 | 451.768 | 0,27% | Aktien |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $23.831.580 | 438.000 | 0,26% | Aktien |
| Baird Financial Group, Inc. | $23.565.461 | 433.109 | 0,26% | Aktien |
| FRANKLIN RESOURCES INC | $23.480.472 | 431.547 | 0,26% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23.347.331 | 429.100 | 0,26% | Kaufoption |
| Assenagon Asset Management S.A. | $23.324.098 | 428.673 | 0,26% | Aktien |
| BANK OF NOVA SCOTIA | $22.837.676 | 419.730 | 0,25% | Aktien |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $22.615.516 | 415.650 | 0,25% | Aktien |
| South Street Advisors LLC | $22.275.019 | 409.392 | 0,24% | Aktien |
| Bridgewater Associates, LP | $21.810.738 | 400.859 | 0,24% | Aktien |
| VICTORY CAPITAL MANAGEMENT INC | $21.480.143 | 394.783 | 0,23% | Aktien |
| ROYAL BANK OF CANADA | $20.031.000 | 368.153 | 0,22% | Aktien |
| SEI INVESTMENTS CO | $19.897.640 | 365.698 | 0,22% | Aktien |
| LAZARD ASSET MANAGEMENT LLC | $18.664.208 | 343.029 | 0,20% | Aktien |
| Nuveen, LLC | $18.299.226 | 336.321 | 0,20% | Aktien |
| Nuveen Asset Management, LLC | $18.252.629 | 548.127 | 0,20% | Aktien |
| NFJ INVESTMENT GROUP, LLC | $17.880.160 | 328.619 | 0,20% | Aktien |
| SAWGRASS ASSET MANAGEMENT LLC | $17.808.447 | 327.301 | 0,19% | Aktien |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $17.565.616 | 322.838 | 0,19% | Aktien |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $17.472.485 | 407.379 | 0,19% | Aktien |
| ING GROEP NV | $16.943.274 | 311.400 | 0,19% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $16.529.758 | 303.800 | 0,18% | Verkaufsoption |
| Brandywine Global Investment Management, LLC | $16.490.117 | 376.229 | 0,18% | Aktien |
| CAPTRUST FINANCIAL ADVISORS | $16.488.532 | 303.042 | 0,18% | Aktien |
| INTECH INVESTMENT MANAGEMENT LLC | $16.262.224 | 298.883 | 0,18% | Aktien |
| HighTower Advisors, LLC | $15.842.121 | 291.162 | 0,17% | Aktien |
| SEIZERT CAPITAL PARTNERS, LLC | $15.411.796 | 283.253 | 0,17% | Aktien |
| Trexquant Investment LP | $14.974.122 | 275.209 | 0,16% | Aktien |
| Clark Capital Management Group, Inc. | $14.792.882 | 271.878 | 0,16% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $14.763.381 | 344.215 | 0,16% | Aktien |
| VAN ECK ASSOCIATES CORP | $14.270.709 | 262.281 | 0,16% | Aktien |
| GLOBEFLEX CAPITAL L P | $13.874.169 | 254.993 | 0,15% | Aktien |
| Sofinnova Investments, Inc. | $13.831.022 | 254.200 | 0,15% | Verkaufsoption |
| JANE STREET GROUP, LLC | $13.815.570 | 253.916 | 0,15% | Aktien |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $13.724.052 | 252.234 | 0,15% | Aktien |
| Voleon Capital Management LP | $13.682.047 | 251.462 | 0,15% | Aktien |
| BLAIR WILLIAM & CO/IL | $13.233.352 | 243.215 | 0,14% | Aktien |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $13.027.000 | 239.418 | 0,14% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12.745.021 | 297.156 | 0,14% | Aktien |
| MERITAGE PORTFOLIO MANAGEMENT | $12.679.099 | 289.279 | 0,14% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $12.516.694 | 230.044 | 0,14% | Aktien |
| Susquehanna Portfolio Strategies, LLC | $12.500.643 | 229.749 | 0,14% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $12.035.492 | 221.200 | 0,13% | Kaufoption |
| Illinois Municipal Retirement Fund | $11.750.764 | 215.967 | 0,13% | Aktien |
Unternehmensinsider 43 Insider · 22 Führungskräfte · 10 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Michael Morrissey | President and CEO | 18. Mai 2026 G | 2.004.327 | 0 | 0 | $0 |
| Christopher J. Senner | EVP and CFO | 18. Mai 2026 S | 952.317 | 0 | 3 | $-4.556.048 |
| Deborah Burke | SVP & Chief Financial Officer | 15. November 2014 M | 18.156 | 0 | 0 | $0 |
| Frank Karbe | EVP and CFO | 15. Februar 2014 M | 93.990 | 0 | 0 | $0 |
| Kristine M Ball | Controller & Interim CFO | 10. Dezember 2003 A | 4.913 | 0 | 0 | $0 |
| Patrick J. Haley | EVP, Commercial | 20. Mai 2026 S | 357.638 | 0 | 7 | $-7.597.268 |
| Brenda Hefti | SVP and General Counsel | 18. Mai 2026 S | 106.762 | 0 | 2 | $-1.154.264 |
| Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | 16. Mai 2025 M | 465.393 | 0 | 0 | $0 |
| Jeffrey Hessekiel | EVP & General Counsel | 15. Mai 2025 S | 693.396 | 0 | 0 | $0 |
| Vicki L Goodman | EVP, Prod Dev & Med Aff &CMO | 3. April 2023 A | 307.654 | 0 | 0 | $0 |
| Peter Lamb | EVP, Scientific Strategy & CSO | 15. Dezember 2022 M | 410.958 | 0 | 0 | $0 |
| Gisela Schwab | Pres, Prod Dev & Med Aff & CMO | 26. Juli 2021 M | 689.078 | 0 | 0 | $0 |
| Pamela A Simonton | EVP and General Counsel | 15. November 2013 M | 17.139 | 0 | 0 | $0 |
| Lupe M Rivera | EVP, Operations | 15. August 2011 M | 19.219 | 0 | 0 | $0 |
| Frances K Heller | EVP, Business Development | 15. Mai 2011 M | 17.125 | 0 | 0 | $0 |
| Ian D Malcolm | VP, STRATEGIC MARKETING | 8. Dezember 2006 A | — | 0 | 0 | $0 |
| Christoph Pereira | VP, Legal Affairs & Secretary | 8. Dezember 2006 A | — | 0 | 0 | $0 |
| Jeffrey Latts | Executive VP, Development | 8. Dezember 2006 A | — | 0 | 0 | $0 |
| Gregory Plowman | Sr VP, CSO | 13. Dezember 2004 A | — | 0 | 0 | $0 |
| Steven P James | Sr VP, Commercial Ops | 10. Dezember 2003 A | — | 0 | 0 | $0 |
| Jane M Green | VP, Corp Communications | 10. Dezember 2003 A | — | 0 | 0 | $0 |
| Geoffrey M Duyk | Pres R&D & CSO | 4. November 2003 S | 941.355 | 0 | 0 | $0 |
| Alan M Garber | Direktor | 21. März 2024 M | 35.703 | 0 | 0 | $0 |
| Jacqueline Wright | Direktor | 1. Juni 2023 A | 51.756 | 0 | 0 | $0 |
| Carl B Feldbaum | Direktor | 9. Februar 2023 M | 18.701 | 0 | 0 | $0 |
| Lance Willsey | Direktor | 26. Mai 2022 A | 424.415 | 0 | 0 | $0 |
| Vincent T Marchesi | Direktor | 26. Mai 2022 A | 93.989 | 0 | 0 | $0 |
| Charles Cohen | Direktor | 6. Juli 2021 M | 261.375 | 0 | 0 | $0 |
| George A Scangos | Direktor | 18. Mai 2020 S | 714.717 | 0 | 0 | $0 |
| FORMELA JEAN FRANCOIS | Direktor | 7. September 2005 S | 584.519 | 0 | 0 | $0 |
| Mary C Beckerle | — | 10. August 2026 S | 16.079 | 0 | 4 | $-1.932.572 |
| Sue Gail Eckhardt | — | 1. Juni 2026 S | 16.079 | 0 | 2 | $-660.828 |
| Jack L Wyszomierski | — | 1. Juni 2026 S | 284.384 | 0 | 2 | $-4.580.661 |
| Tomas J. Heyman | — | 27. Mai 2026 A | 50.649 | 0 | 0 | $0 |
| Bob Oliver | — | 27. Mai 2026 A | 29.487 | 0 | 2 | $-1.325.340 |
| Julie Smith | — | 27. Mai 2026 A | 28.957 | 0 | 3 | $-4.687.346 |
| Maria C Freire | — | 27. Mai 2026 A | 109.186 | 0 | 1 | $-949.164 |
| Stelios Papadopoulos | — | 27. Mai 2026 A | 1.197.595 | 0 | 1 | $-4.355.000 |
| George Poste | — | 27. Mai 2026 A | 127.199 | 0 | 1 | $-2.742.600 |
| Dana Aftab | — | 26. Mai 2026 S | 594.741 | 0 | 4 | $-7.701.255 |
| Frank Mccormick | — | 6. Dezember 2013 A | — | 0 | 0 | $0 |
| Scott J. Garland | — | 18. September 2013 A | — | 0 | 0 | $0 |
| Jason S Fisherman | — | 8. September 2005 S | 7.881 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Farallon Capital Management, L.L.C., Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Roberts, Jr., Thomas G., Saito Edric C., Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. | 14. August 2026 | 5,60% | Änderung | — | SEC |
| Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Fried, Richard B, Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Patel, Rajiv A., Roberts, Jr., Thomas G., Saito Edric C., Seybold, William, Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. ×8 Einreichungen | 5. Januar 2026 | 5,90% | Änderung | — | SEC |
| Caligan Partners LP, David Johnson ×3 Einreichungen | 2. Juni 2023 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 29. November 2001 | — | Erste Einreichung | M&A / Verkauf | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 153 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IDNA · iShares Trust | 3,30% | 139.059 SH | 19. August 2026 | Täglich |
| SAWG · ETF Series Solutions | 2,82% | 1.599 NS | 30. April 2026 | N-PORT |
| CANC · Tema ETF Trust | 2,78% | 96.885 NS | 31. Mai 2026 | N-PORT |
| XMHQ · Invesco Exchange-Traded Fund Trust | 2,62% | 2.778.815 SH | 19. August 2026 | Täglich |
| PBE · Invesco Exchange-Traded Fund Trust | 2,48% | 181.529 SH | 19. August 2026 | Täglich |
| MCOW · Pacer Funds Trust | 2,38% | 528 NS | 30. April 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 2,24% | 441.186 NS | 30. April 2026 | N-PORT |
| LYLD · Cambria ETF Trust | 2,01% | 2.722 NS | 30. April 2026 | N-PORT |
| AZTD · Tidal Trust I | 1,92% | 18.950 NS | 30. April 2026 | N-PORT |
| GRPM · Invesco Exchange-Traded Fund Trust | 1,82% | 172.947 SH | 19. August 2026 | Täglich |
| BBP · ETFis Series Trust I | 1,74% | 23.148 NS | 30. April 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 1,61% | 1.596 NS | 30. April 2026 | N-PORT |
| BUL · Pacer Funds Trust | 1,45% | 41.520 NS | 30. April 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,39% | 306.870 NS | 30. April 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1,36% | 5.563 NS | 30. April 2026 | N-PORT |
| RFG · Invesco Exchange-Traded Fund Trust | 1,28% | 86.321 SH | 19. August 2026 | Täglich |
| COWG · Pacer Funds Trust | 1,26% | 616.432 NS | 30. April 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 1,26% | 62.199 SH | 19. August 2026 | Täglich |
| TAX · EA Series Trust | 1,13% | 5.692 NS | 29. Mai 2026 | N-PORT |
| CALF · Pacer Funds Trust | 1,07% | 829.382 NS | 30. April 2026 | N-PORT |
| AFMC · First Trust Exchange-Traded Fund VI… | 1,03% | 32.938 NS | 31. Mai 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 1,00% | 116.281 NS | 30. April 2026 | N-PORT |
| IBB · iShares Trust | 0,94% | 1.808.523 SH | 19. August 2026 | Täglich |
| AGNG · Global X Funds | 0,92% | 14.988 NS | 31. Mai 2026 | N-PORT |
| OASC · Unified Series Trust | 0,91% | 15.171 NS | 31. Mai 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,90% | 25.550 NS | 30. April 2026 | N-PORT |
| FLOW · Global X Funds | 0,90% | 5.093 NS | 31. Mai 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,89% | 13.913 SH | 19. August 2026 | Täglich |
| VAMO · Cambria ETF Trust | 0,88% | 16.470 NS | 30. April 2026 | N-PORT |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,72% | 248.016 SH | 19. August 2026 | Täglich |
| FLRG · FIDELITY COVINGTON TRUST | 0,72% | 45.672 NS | 30. April 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,69% | 7.149 NS | 31. Mai 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,68% | 82.717 NS | 31. Mai 2026 | N-PORT |
| BIB · ProShares Trust | 0,66% | 9.600 NS | 31. Mai 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,64% | 4.091 NS | 31. Mai 2026 | N-PORT |
| VUSE · ETF Series Solutions | 0,63% | 85.930 NS | 31. Mai 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,60% | 2.080 NS | 30. April 2026 | N-PORT |
| QGRO · AMERICAN CENTURY ETF TRUST | 0,58% | 255.026 NS | 31. Mai 2026 | N-PORT |
| PDP · Invesco Exchange-Traded Fund Trust | 0,58% | 164.295 SH | 19. August 2026 | Täglich |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,53% | 19.762 NS | 31. Mai 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 0,51% | 502 NS | 30. April 2026 | N-PORT |
| VFQY · VANGUARD WELLINGTON FUND | 0,49% | 42.746 SH | 19. August 2026 | Täglich |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,48% | 64.828 NS | 30. April 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,47% | 5.095 NS | 30. April 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,44% | 146.786 SH | 19. August 2026 | Täglich |
| IQSM · New York Life Investments ETF Trust | 0,44% | 30.864 NS | 30. April 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,41% | 47.960 NS | 30. April 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,40% | 33.304 SH | 19. August 2026 | Täglich |
| AVMV · AMERICAN CENTURY ETF TRUST | 0,39% | 47.706 NS | 31. Mai 2026 | N-PORT |
| GQQQ · EA Series Trust | 0,38% | 11.012 NS | 29. Mai 2026 | N-PORT |